Cantor Fitzgerald initiates coverage on Helicos BioSciences Corp. (Nasdaq: HLCS) with a Buy rating and $14 price target.

The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE